Deferiprone Levels and Effects while Breastfeeding
Summary of Use during Lactation
Deferiprone is likely actively transported into milk through binding with lactoferrin.[1] Because no information is available on the use of deferiprone during breastfeeding and it is orally absorbed, an alternate drug is preferred, especially while nursing a newborn or preterm infant. Australian guidelines recommend against breastfeeding during deferiprone treatment.[2] The US manufacturer recommends withholding breastfeeding for 2 weeks after the last dose.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Asmari M, Waqas M, Ibrahim AE, et al. Microscale thermophoresis and molecular modelling to explore the chelating drug transportation in the milk to infant. Molecules. 2022:27. [PMC free article: PMC9319837] [PubMed: 35889479]
2.
Ho PJ, Tay L, Lindeman R, et al. Australian guidelines for the assessment of iron overload and iron chelation in transfusion-dependent thalassaemia major, sickle cell disease and other congenital anaemias. Intern Med J. 2011;41:516–24. [PubMed: 21615659]
Substance Identification
Substance Name
Deferiprone
CAS Registry Number
30652-11-0
Drug Class
Breast Feeding
Lactation
Milk, Human
Chelating Agents
Iron Chelating Agents
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
